There are currently 67 active clinical trials seeking participants for Hepatocellular Carcinoma research studies. The states with the highest number of trials for Hepatocellular Carcinoma participants are California, Guangdong, Texas and New York.
Multi-analyte Blood Test Clinical Trial
NCT05199259
Recruiting
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Providence Facey Medical Foundation, Mission Hills, California +6 locations
Conditions: Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Register for Updates
Liver Cancer Disparities in American Indian and Alaska Native Persons
NCT05304234
Recruiting
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Cherokee Nation Health Service, Tahlequah, Oklahoma
Conditions: Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B
Register for Updates
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044
Recruiting
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovaria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +2 locations
Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Register for Updates
Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma
NCT04797884
Recruiting
The primary goals of this study are to compare overall survival and quality of life in subjects with Child-Pugh A or B advanced hepatocellular carcinoma when treated with a device emitting radiofrequencies modulated at specific frequencies or with a device emitting unmodulated radiofrequencies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2023
Locations: Tampa General Hospital, Tampa General Cancer Center, Tampa, Florida +6 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505
Recruiting
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer
Register for Updates
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
NCT03482102
Recruiting
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: * Durvalumab * Tremelimumab * Radiation Therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Register for Updates
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
NCT03686709
Recruiting
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2018
Locations: University of Tennessee Medical Center, Knoxville, Tennessee
Conditions: Hepatocellular Carcinoma, Radiation Exposure
Register for Updates